TriSalus Life Sciences (TLSI) AI Stock Analysis

• Market Cap: $243.35M
• Dividend Yield: N/A
• Average Volume (3M): 132.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: 45.50%
• EPS Growth: 53.07%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.27
• Shares Outstanding: 49,867,280
• 10 Day Avg. Volume: 176,909
• 30 Day Avg. Volume: 132,392
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 5.80
• Enterprise Value/Gross Profit: 6.78
• Enterprise Value/Ebitda: -8.47
• 1Y Price Target: $11.60
• Price Target Upside: 138.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 48 Neutral
• Price Target: $5.00 ▲(2.67% Upside)

TriSalus Life Sciences' overall stock score is primarily impacted by its financial performance challenges, including negative equity and ongoing losses. While the earnings call provided some positive insights into revenue growth and strategic initiatives, the company's valuation and technical indicators do not offer strong support, resulting in a lower overall score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion and sustainability.

Product Portfolio Expansion

Expanding the product portfolio enhances competitive positioning and diversifies revenue streams, contributing to long-term growth potential.

Successful Capital Raise

The capital raise strengthens the balance sheet, providing resources for strategic initiatives and reducing financial risk, supporting future growth.

Negative Factors

Negative Equity

Negative equity indicates financial instability, limiting the company's ability to leverage financing and posing long-term solvency risks.

Persistent Losses

Ongoing losses highlight operational inefficiencies and profitability challenges, which could hinder sustainable growth and investor confidence.

Negative Cash Flow

Negative cash flow from operations suggests reliance on external financing, which can strain resources and impact long-term financial health.

TriSalus Life Sciences Business Overview & Revenue Model

Company Description

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

How the Company Makes Money

TriSalus Life Sciences generates revenue through the development and commercialization of its proprietary drug delivery systems and therapeutic agents. The company earns income by licensing its technologies to pharmaceutical partners and through the sale of its products. Key revenue streams include licensing fees, royalties from partnered drugs, and direct sales of its therapies and delivery systems. Significant partnerships with leading pharmaceutical companies and healthcare providers contribute to its earnings by expanding the reach and application of its technologies.

TriSalus Life Sciences Financial Statement Overview

Summary

TriSalus Life Sciences exhibits strong revenue growth but faces significant financial challenges, including persistent losses, negative equity, and reliance on external financing. These factors indicate substantial risks related to profitability and cash flow sustainability.

Income Statement

TriSalus Life Sciences has shown significant revenue growth over the years, with a 73% increase from 2022 to 2023 and a 59% increase from 2023 to 2024. However, the company remains unprofitable, with consistent negative net income and negative EBIT and EBITDA margins, indicating ongoing operational and profitability challenges.

Balance Sheet

The balance sheet reveals a problematic financial structure with substantial negative stockholders' equity, indicating that liabilities exceed assets. High levels of debt relative to equity suggest potential solvency concerns, although the debt-to-equity calculation is not feasible due to negative equity. The equity ratio is negative, reinforcing the company's financial instability.

Cash Flow

The cash flow statement highlights significant negative operating cash flows, which indicate challenges in generating cash from core operations. Despite a positive trend in financing cash flows, free cash flow remains negative, pointing to ongoing cash burn and reliance on external financing to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	32.14M	29.43M	18.51M	12.40M	8.40M	5.43M
Gross Profit	27.51M	25.33M	15.91M	10.14M	7.21M	3.24M
EBITDA	-22.02M	-36.16M	-58.30M	-46.76M	-23.57M	-25.32M
Net Income	-27.21M	-33.23M	-59.04M	-47.19M	-28.84M	-31.83M
Balance Sheet
Total Assets	28.63M	23.97M	25.73M	22.00M	37.84M	252.01M
Cash, Cash Equivalents and Short-Term Investments	13.00M	8.53M	11.78M	9.41M	30.30M	4.49M
Total Debt	33.12M	23.63M	1.59M	1.96M	544.00K	42.18M
Total Liabilities	62.99M	49.87M	51.66M	198.32M	167.44M	23.50M
Stockholders Equity	-34.37M	-25.89M	-25.94M	-176.33M	30.90M	228.52M
Cash Flow
Free Cash Flow	-35.51M	-41.19M	-51.17M	-33.10M	-23.95M	-1.22M
Operating Cash Flow	-34.48M	-40.84M	-50.58M	-32.31M	-22.70M	-677.60K
Investing Cash Flow	-993.00K	-345.00K	-2.12M	-1.79M	-2.26M	-250.00M
Financing Cash Flow	44.50M	37.94M	54.63M	13.46M	50.77M	252.01M

TriSalus Life Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.87
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLSI, the sentiment is Positive. The current price of 4.87 is below the 20-day moving average (MA) of 4.91, above the 50-day MA of 4.62, and below the 200-day MA of 5.04, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 52.45 is Neutral, neither overbought nor oversold. The STOCH value of 72.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TLSI.

TriSalus Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OM	56 Neutral	279.84M	-0.73	-63.25%	―	2.47%	56.93%
TLSI	48 Neutral	$243.35M	―	271.41%	―	45.50%	53.07%
CVRX	48 Neutral	196.92M	-3.54	-90.19%	―	23.11%	18.06%
MYO	44 Neutral	32.13M	-4.18	-25.02%	―	93.07%	13.25%
LNSR	44 Neutral	151.69M	-2.95	532.08%	―	29.34%	-283.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

TriSalus Life Sciences Corporate Events

TriSalus Life Sciences Grants CFO Stock Options

On August 25, 2025, TriSalus Life Sciences, Inc. approved an increase in the annual compensation of their Chief Financial Officer, Mr. David Patience, from $450,000 to $550,000. Additionally, on August 28, 2025, the company granted Mr. Patience stock options to purchase 249,899 shares of common stock, contingent upon the company achieving or exceeding $75 million in revenue over a twelve-month period before the end of 2027.

The most recent analyst rating on (TLSI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.